PMID- 34581242
OWN - NLM
STAT- MEDLINE
DCOM- 20220223
LR  - 20220428
IS  - 1532-2513 (Electronic)
IS  - 0892-3973 (Linking)
VI  - 43
IP  - 6
DP  - 2021 Dec
TI  - Sarsasapogenin and fluticasone combination improves DNFB induced atopic 
      dermatitis lesions in BALB/c mice.
PG  - 767-777
LID - 10.1080/08923973.2021.1981375 [doi]
AB  - OBJECTIVE: Atopic dermatitis (AD) is a pruritic, chronic, relapsing inflammatory 
      skin disease. The research aims to study the effects of Sarsasapogenin and its 
      combination with Fluticasone in 2, 4-Dinitrofluorobenzene (DNFB) induced atopic 
      dermatitis in BALB/c mice. MATERIAL AND METHODS: Thirty male Balb/c mice were 
      divided into 5 groups: (i) Normal control (NC), (ii) Disease control (DNFB), 
      (iii) Sarsasapogenin (SG) (50 microg/mice), (iv) Fluticasone (FC) (50 microg/mice), (v) 
      Sarsasapogenin + Fluticasone (SG + FC) combination (25 microg/mice). Dermatitis was 
      induced by repeated application of DNFB in Balb/c mice. On topical application of 
      SG, FC, and SG + FC combination on the ear and skin lesions, body weight, ear 
      weight, ear thickness, erythema score, spleen weight, cytokines, immunoglobulin E 
      (IgE) levels, nitric oxide (NO) level, hematological parameters, and oxidative 
      stress markers were evaluated. Histological analysis of the ear tissue was also 
      done. RESULTS: The results stated that SG and SG + FC treatment to mice 
      considerably decrease the ear weight, ear thickness, spleen weight, serum IgE, 
      cytokines, NO levels, and restoration of antioxidant stress markers with 
      elevation in the hematological parameters. The observations were further 
      confirmed by histopathological analysis of ear tissue. CONCLUSION: These data 
      specify that SG has been demonstrated as a probable therapy for the treatment of 
      allergic skin diseases in combination with FC by decreasing its dose from 50 to 
      25 microg/mice to avoid the chronic side effects of FC. Hence, it can be concluded 
      that SG and SG + FC combination significantly improved the AD-like symptoms in 
      the DNFB sensitized mice through mitigating the production of proinflammatory 
      mediators and restoration of oxidative stress markers.
FAU - Mandlik, Deepa S
AU  - Mandlik DS
AD  - Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Pune, 
      India.
FAU - Mandlik, Satish K
AU  - Mandlik SK
AD  - Bharati Vidyapeeth (Deemed to be University), Poona College of Pharmacy, Pune, 
      India.
FAU - Patel, Snehal S
AU  - Patel SS
AD  - Institute of Pharmacy, Nirma University, Ahmedabad, India.
LA  - eng
PT  - Journal Article
DEP - 20210928
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Dermatologic Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Spirostans)
RN  - CFS802C28F (sarsasapogenin)
RN  - CUT2W21N7U (Fluticasone)
RN  - D241E059U6 (Dinitrofluorobenzene)
SB  - IM
MH  - Animals
MH  - Dermatitis, Atopic/chemically induced/*drug therapy/metabolism
MH  - Dermatologic Agents/*administration & dosage
MH  - Dinitrofluorobenzene/*toxicity
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Female
MH  - Fluticasone/*administration & dosage
MH  - Inflammation Mediators/antagonists & inhibitors/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Spirostans/*administration & dosage
MH  - Toxicity Tests, Acute/methods
OTO - NOTNLM
OT  - 2
OT  - 4-dinitrofluorobenzene
OT  - Atopic dermatitis
OT  - fluticasone
OT  - histopathology
OT  - pro-inflammatory cytokines
OT  - sarsasapogenin
EDAT- 2021/09/29 06:00
MHDA- 2022/02/24 06:00
CRDT- 2021/09/28 08:53
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2022/02/24 06:00 [medline]
PHST- 2021/09/28 08:53 [entrez]
AID - 10.1080/08923973.2021.1981375 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2021 Dec;43(6):767-777. doi: 
      10.1080/08923973.2021.1981375. Epub 2021 Sep 28.